[Ip-health] MSF responds to new leak of Trans-Pacific Partnership text on intellectual property for pharmaceuticals

Michelle French Michelle.French at newyork.msf.org
Wed Aug 5 01:02:32 PDT 2015

(with corrected KEI link)


MSF responds to new leak of Trans-Pacific Partnership text on intellectual 
property for pharmaceuticals

August 4, 2015 -- Following last week’s round of negotiations on the 
Trans-Pacific Partnership (TPP) agreement in Maui, Hawaii, Knowledge 
Ecology International (KEI) has published a leaked copy of sections of the 
secret TPP negotiating text on Intellectual Property, including 
information on what’s being proposed for pharmaceutical products. The 
negotiating text is dated May 11, 2015, and reflects the state of the text 
right before the Maui rounds of the negotiation, which ended Friday, July 
31, 2015 without concluding the deal. 

A preliminary review of the leaked text confirms that provisions that will 
harm access to medicines, primarily being proposed by the United States 
and Japan, remain in the text.  In addition, the text shows that many 
negotiating countries continue to object to the inclusion of these 
provisions, which will strengthen, lengthen and create new patent and 
regulatory monopolies for pharmaceutical products.   MSF has called on all 
negotiating countries to reject any provisions that will raise the price 
of medicines and reduce the availability of price-lowering generic 

Statement by Judit Rius Sanjuan, U.S. manager and legal policy advisor for 
MSF’s Access Campaign:
“This new leaked text confirms some of the most concerning provisions that 
will have a devastating impact on global health remain in the text, 
including data exclusivity for biologic products and mandatory secondary 
patenting.  The text also confirms that the U.S. is walking away from 
previous public health commitments made as part of the New Trade Policy or 
‘May 10 Agreement’ with Peru, Colombia and Panama. MSF calls on all 
negotiating countries to reject provisions that will grant pharmaceutical 
companies additional monopoly protections, delay generic competition and 
keep medicines out of reach of MSF medical operations and millions of 

Faced with the intransigence of the U.S. government on these issues during 
the negotiations in Hawaii last week, we see that a few countries are 
moving towards negotiating ‘carve-outs’ that would exempt them from 
changing their existing national laws, but would then leave the rest of 
the TPP countries facing the full implementation of these harmful 
provisions.  What we really need is these provisions removed completely 
from the TPP, not special deals that exempt only specific countries from 
these rules.”

Leaked text: http://keionline.org/node/2308 
Recent MSF media statements: 
More information: http://msfaccess.org/TPP


Michelle French
Sr. Communications Manager, MSF Access Campaign
Doctors Without Borders\Médecins Sans Frontières (MSF)
Office: +1.212.763.5735 | Mobile: +1.646.552.4600
michelle.french at newyork.msf.org | Skype: michellejfrench
www.msfaccess.org | twitter.com/MSF_access | www.facebook.com/MSFaccess

More information about the Ip-health mailing list